Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic

Mayo Clinic Proceedings

Volumn 85, Issue 2, 2010, Pages 131-138

  Wetter, David A ^a   Camilleri, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAMAZEPINE; CEFDINIR; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NABUMETONE; NEVIRAPINE; OXICAM DERIVATIVE; PHENOBARBITAL; PHENYTOIN; ROFECOXIB; SERTRALINE; SULFONAMIDE; THALIDOMIDE;

ADULT; ANEMIA; ARTICLE; BULLOUS SKIN DISEASE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONJUNCTIVITIS; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSPNEA; EOSINOPHIL; EXTRAVASATION; EYE DISEASE; EYE INFLAMMATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; INCONTINENTIA PIGMENTI; INTENSIVE CARE UNIT; KERATINOCYTE; MALE; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOSA; MYCOPLASMA PNEUMONIAE; NEUTROPHIL; PARAKERATOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SKIN BIOPSY; SKIN INFILTRATE; SKIN MANIFESTATION; SKIN NECROSIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRACHEITIS;

EID: 75749150504     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0379     Document Type: Article

References (27)

1. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181-200.
2. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child. 1922; 24:526-533.
3. Thomas BA. The so-called Stevens-Johnson syndrome. Br Med J. 1950; 1(4667):1393-1397.
4. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5): 539-543.
5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
6. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135(1):6-11.
7. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683-687.
8. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol. 1997;19(2):127-132.
9. Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol. 1995;131(11):1268-1272.
10. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28S-30S.
11. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839-842.
12. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC, SCAR Study Group. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-1024.
13. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44. Epub 2007 Sep 6.
14. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008;74(3):238-240.
15. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56(4):419-425. Epub 2007 Sep 1.
16. Kamaliah MD, Zainal D, Mokhtar N, Nazmi N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol. 1998;37(7):520-523.
17. Halevy S, Ghislain PD, Mockenhaupt M, et al, EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32. Epub 2007 Oct 24.
18. Horowitz SB, Stirling AL. Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy. 1999;19(10):1177-1180.
19. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5, pt 1):757-760.
20. Levy M, Shear NH. Mycoplasma pneumoniae infections and Stevens-Johnson syndrome: report of eight cases and review of the literature. Clin Pediatr (Phila). 1991;30(1):42-49.
21. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83(4):347-352.
22. Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007;119(4):e1002-1005. Epub 2007 Mar 12.
23. Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction? J Am Acad Dermatol. 2005;52(2):312-315.
24. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20(2):219-223.
25. Dobrosavljevic D, Milinkovic MV, Nikolic MM. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol. 1999;13(1):59-61.
26. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33-40. Epub 2007 Oct 4.
27. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91(8):1048-1053. Epub 2007 Feb 21.